
compani
jul pm et
summari lead produc prescript drug offer wide rang treatment
neurolog disord diabet cancer condit
nm price-to-earnings oper ep
risk assess reflect gener challeng
compani brand patent well drug develop
regulatori risk howev off-set
oct ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
see sale rise aid
new product see trulic sale
taltz sale cyramza sale
among older drug see humalog
forteo sale
respect alimta sale declin
octob fda approv
verzenio treat breast cancer
june fda approv baricitinib
olumi treat moder sever
rheumatoid arthriti dosag
dosag concern safeti
particularli pulmonari embol deep
vein thrombosi note dose
approv europ expect
work fda dose believ
dose key gain market share
data galcanezumab treat cluster
headach note signific competit
indic novar receiv
fda approv may aimovig teva
septemb fda
date fremanezumab
lanabecestat treat alzheim diseas
clinic data show compound
unlik meet clinic trial primari
hold recommend base
modest sale growth balanc sale
growth new product partial off-set
patent expir lower sale
multipl sclerosi franchis recent
pipelin failur juli announc
spin-off
expect complet ipo less
elanco year-end
subsequ dispos remain
ownership view spin-off
posit free resourc
improv growth expect launch new
product
cautiou goal juli reach
deal gener manufactur extend
exclus ciali septemb
expect high-single-digit declin
sale europ think
achiev annual sale growth
improv gross margin
oper expens improv less
risk recommend target
includ lower-than-expect sale new
drug failur develop commerci
pipelin
target price
forward ep estim
line peer
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
vice presid
compani
corpor overview co lead maker prescript drug offer wide rang
treatment neurolog disord diabet cancer condit compani anim health
busi oper elanco divis develop manufactur market product
food anim companion anim compani product sold approxim countri
compani endocrinolog product includ humalog insulin analog treatment diabet
humulin human insulin recombin dna origin treatment diabet trajenta
treatment type diabet jentadueto combin tablet linagliptin trajenta metformin
hydrochlorid use treatment type diabet jardianc treatment type diabet
approv europ japan trulic treatment type diabet approv
 europ glyxambi combin tablet linagliptin empagliflozin jardianc
treatment type diabet approv januari forteo treatment
osteoporosi postmenopaus women men high risk fractur glucocorticoid-induc
osteoporosi men postmenopaus women evista prevent treatment
osteoporosi postmenopaus women reduct risk invas breast cancer
postmenopaus women osteoporosi postmenopaus women high risk invas breast
cancer humatrop treatment human growth hormon defici certain pediatr growth
condit axiron topic solut testosteron appli underarm applic replac
therapi men certain condit associ defici absenc testosteron
compani neurosci product includ cymbalta treatment major depress disord
diabet peripher neuropath pain gener anxieti disord manag
fibromyalgia chronic musculoskelet pain due chronic low back pain chronic pain due
osteoarthr zyprexa treatment schizophrenia acut mix manic episod associ
bipolar disord bipolar mainten strattera treatment attention-deficit hyperact
disord prozac treatment major depress disord obsessive-compuls disord bulimia
nervosa panic disord amyvid radioact diagnost agent positron emiss tomographi
imag beta-amyloid neurit plaqu brain adult patient cognit impair
evalu alzheim diseas caus cognit declin
compani anim health segment elanco includ food product anim rumensin
cattl feed addit improv feed effici growth also control prevent coccidiosi
posilac protein supplement improv milk product dairi cow paylean optaflexx lean
perform enhanc swine cattl respect tylan antibiot use control certain
diseas cattl swine poultri micotil pulmotil pulmotil ac antibiot use treat respiratori
diseas cattl swine poultri respect coban monteban maxiban anticoccidi agent
use poultri surmax sold maxu countri perform improv swine
compani product companion anim includ trifexi monthli chewabl tablet dog
kill flea prevent flea infest prevent heartworm diseas control intestin parasit
infect comforti chewabl tablet kill flea prevent flea infest dog
impact major develop januari compani complet acquisit novarti
anim health product acquir novarti deal includ denagard antibiot control
treatment respiratori enter diseas swine poultri milbemax spectrum intestin
wormer given monthli also offer prevent heartworm sentinel outsid
monthli tablet prevent flea popul concurr prevent heartworm diseas
treatment roundworm hookworm whipworm dog atopica treatment chronic
manifest atop dermat dog symptomat treatment chronic allerg
dermat cat fortekor treatment congest heart failur dog reduct
proteinurea associ chronic kidney diseas cat
pipelin spend total billion billion billion billion
equal sale respect one highest
 d-to-sal ratio drug industri industri averag approxim sale april
compani pipelin new chemic entiti new molecular entiti
nme phase clinic trial phase ii clinic trial
financi trend sale risen billion billion repres
three-year compound annual growth rate compound-annual-growth-rate growth new product sale partial
off-set impact patent expir sever product gross margin improv
adjust ep rose repres three-year
compound-annual-growth-rate
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
fundament outlook pharmaceut
sub-industri next month neutral
although issu high drug price remain
overhang industri believ
impact lessen believ
trump administr push
regulatori chang forc drug price
may trump administr releas
drug price blueprint american patient
first view offer littl polici
regulatori chang rein escal drug
price rather see consolid
amongst largest drug purchas
health insur pharmaci benefit manag
hospit effort increas buy
firm announc rais
price drug year
signific portion firm organ
follow june drug price
innov work group draft
execut order aim tackl high drug
price draft focus reduc regul
method increas competit lower
intellectu properti right scale back
discount given hospit serv lower
incom patient import note mani
individu serv work group
former pharmaceut execut
like cfra view put forward
separ believ top-lin pressur
patent expir mani top-sel drug
bottom anticip modest
organ sale increas low-singl digit
also see expand sale new
innov drug therapi margin
improv accru cost restructur
merger synergi
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev repeal individu mandat
compon requir
peopl health insur pay fine
includ tax cut job act
pass decemb repeal
mandat effect januari
expect fewer insur patient
despit advers effect patent
expir pressur high drug price
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri number
new molecular entiti approv rebound
approv number
approv sinc
record approv follow robust
approv
approv
 pharmaceut index
increas versu rise
 composit index year date
juli pharmaceut
declin vs rise
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
analyst research note compani news
keep target peer
ep estim faster growth ep vs
ahead estim mainli cost cut sale rose volum gain
solid sale new product trulic taltz partial off-set modest
declin ciali alimta complet acquisit colucid
pharmaceut includ phase compound lasmiditan treat migrain
provid timelin baricitinib recent receiv
non-approv complet respons letter fda /jeffrey loo cfa
compani partner nr receiv
complet respons letter non-approv baricitinib treat
rheumatoid arthriti fda request addit dose safeti data
believ requir new clinic trial push back potenti approv
year surpris view previous releas data
solid sinc baricitinib recent receiv eu approv although view
pipelin posit high profil disappoint pipelin
news past month solanezumab fail alzheim trial
li compani keep target
peer ep estim faster earn
growth ep vs ahead estim set
ep estim sale rose driven new drug trulic
cyramza jardianc partial off-set gener impact older drug
mid-januari agre acquir colucid pharma clcd nr
subject approv deal add lasmiditan treat migrain
phase pipelin guid sale ep
et cfra keep hold opinion share eli li
rais target in-lin peer
forward ep estim adjust ep vs
ahead estim aid lower-than-expect oper
cost due cost reduct effort improv product rais
ep estim ep estim
sale rose pharmaceut sale driven new product
trulic taltz cyramza basaglar also encourag
pipelin advanc phase trial tanezumab treat
osteoarthr met three co-primari endpoint empagliflozin treat
diabet also met primari endpoint announc spin
elanco anim health unit ipo say maxim
after-tax valu sharehold view spin-off posit
anim health unit struggl past year soft sale /jeffrey
et cfra keep hold opinion share eli lilli
compani keep target price line
peer ep estim rais
ep estim ep vs
ahead estim sale aid fx benefit rose driven
increas demand new drug trulic talz
basaglar oper cost fell drive oper
margin bp diabet volum growth rose note continu
soft anim health expect growth unit
separ fda advisori panel recommend approv baricitinib treat
moderate-to-sever rheumatoid arthriti dosag
approv dosag safeti concern particularli pulmonari
embol deep vein thrombosi note dose approv
europ expect work fda dose believ
dose key gain market share /jeffrey loo cfa
compani keep target
ep estim tax reform benefit ep
vs ahead estim sale rose pharmaceut
sale driven strong sale new drug trulic taltz
jardianc top sell drug humalog ciali fell
respect humalog sale impact lower price due discount
rebat also concern declin anim health lower
volum market access headwind competit pressur posilac
et cfra keep hold opinion share eli lilli
compani rais target peer
forward ep estim faster growth ep
vs in-lin estim rais ep
estim sale rose driven new
drug trulic taltz world-wide diabet sale rose
explor potenti spin-off sale expect
provid updat elanco sale
second largest anim health compani view potenti move posit
compani keep target above-p
forward ep estim ep vs
ahead estim rais ep estim
sale rose driven trulic taltz see declin sale
matur product evalu option baricitnib includ new
trial believ nda resubmiss would least month away
view recent patent deal gener manufactur regard ciali
posit exclus septemb origin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn per
share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
compani
